% 0期刊文章%安东尼红色%一个杰弗里·科恩% Daniela Piani Meier % Davorka Tomic %一个香农Ritter %布鲁斯克里族% T残疾Fingolimod的长期影响:绝对趋势分析8年来(P3.080) % D J神经病学2016% % P P3.080 X % V % 86% N 16补充目的:进行长期的趋势分析复发缓和多发性硬化患者残疾的进化(名RRMS)自由和自由。首页背景:Fingolimod降低残疾的病程2年与安慰剂比较,第三阶段自由试验。长期变化扩大残疾状态量表(eds)得分集中自由人群可能揭示见解残疾进化和早期的影响,连续治疗。方法:从基线事后分析96个月(包括提单)患者随机fingolimod 0.5毫克(N = 783)或安慰剂(N = 773) 24个月自由试验,这些试验持续或切换到fingolimod 0.5毫克扩展,和那些继续观察长期试验fingolimod 0.5毫克。残疾进化分类:“最小”(eds±0.5分的变化从提单提单≤5.5,0点如果提单> 5.5);“改善”/“恶化”(增加/减少eds分数≥1.0点的提单,确认≥6个月或确诊和持续到24日或96年个月);”或“脉动”(变化不同于其他模式定义)。稳定/改进的组合类别“最小”和“改善”。结果:在24个月,更少的患者“恶化”fingolimod比安慰剂(13.3 vs 18.5 [percnt] (n = 90) [percnt] (n = 118);p = 0.0095),但两组,大部分被归类为“最小”(35.6 vs 32.6 [percnt] (n = 242) [percnt] [n = 208])或“脉动”(37.0 vs 32.9 [percnt] (n = 251) [percnt] [n = 210])。 At 96 months, there were still proportionately fewer continuous fingolimod patients than placebo-to-fingolimod switch patients ‘worsening’ (26.7[percnt] [n=36] vs 34.5[percnt] [n=40]; p=0.18). At 96 months, 55.6[percnt] (n=75) of patients on fingolimod were ‘stable/improving’ with proportionately more ‘improving’ (30.4[percnt] [n=41]) than at 24 months (14.1[percnt] [n=96]; p<0.0001), and fewer patients were in the ‘minimal’ (16.4-25.2[percnt]) or ‘fluctuating’ (17.8-18.1[percnt]) categories. Conclusions: Over 2 years, disability changed minimally or fluctuated in patients with RRMS. After 8 years, disability in the majority of patients treated with fingolimod was stable or had improved.Disclosure: Dr. Reder has received personal compensation for activities with Acorda, Bayer, Biogen, EMD Serono, Inc., Genentech, Genzyme, Novartis, Pfizer, Questcor/Malinkrodt, Sanofi, and Teva Pharmaceuticals. Dr. Cohen received personal compensation for activities with Genentech, Genzyme, Novartis, and Teva as a consultant or speaker. Dr. Cohen has received personal compensation in an editorial capacity for Multiple Sclerosis Journal-Experimental, Translationa Dr. Piani Meier has received personal compensation for activities with Novartis as an employee. Dr. Tomic has received personal compensation for activities with Novartis as an employee. Dr. Ritter has received personal compensation for activities with Novartis. Dr. Cree has received personal compensation for activities with Abbvie, Biogen Idec, EMD Serono, Genzyme/sanofi aventis, Medimmune, Novartis and Teva. Dr. Cree has received research support from Acorda, EMD Serono, Hoffman La Roche, MedImmune, Novartis aMonday, April 18 2016, 8:30 am-7:00 pm %U